المستويات والأنماط الجينية المتعددة للانترلوكين -6 في مرضى التهاب المفاصل الرثوي في محافظة بابل/العراق

الموضوعات

طب

روابط وملفات

التعريف والنوع

رقم الوثيقة

011bc49c-9d08-4da6-8512-2c879361b3e7

رقم العقد

0

نوع الوسائط

Crawler

نوع المحتوى

الرسائل العلمية

صيغة المصدر

رسائل ماجيستير

نوع الملف

pdf text

أسماء الملفات

998084_1.pdf

بيانات النشر

ترجمة العنوان

Interleukin -6 Gene Polymorphisms and Levels in Rheumatoid Arthritis Patients in Babylon Province / Iraq

ألقاب المؤلفين

[{"name_ar":"سارة حسين عيدان","title_ar":"اعداد","title_en":"Preparation"},{"name_ar":"صباح جاسم الربيعي","title_ar":"اشراف","title_en":"Supervision"},{"name_ar":"عبد السميع حسن الطائي","title_ar":"اشراف","title_en":"Supervision"}]

اللغة

English

المصدر والدورية

اسم المصدر

المستويات والأنماط الجينية المتعددة للانترلوكين -6 في مرضى التهاب المفاصل الرثوي في محافظة بابل/العراق

المحتوى والصفحات

عدد الصفحات

0

ترجمة الملخص

Rheumatoid arthritis (RA) is a chronic systemic inflammatory autoimmune disease characterized by persistent symmetric polyarthritis that commonly affects the joints of the hands and feet. This study aims to investigate the possible association between interleukin-6 (IL-6) levels and (-174G/C) IL-6 promoter polymorphism in RA in Babylon Province. A total of 60 RA patients and 60 healthy controls matched for age and sex were included in this case-control study. Measurement of serum IL-6 and serum anti-cyclic citrullinated peptide (ACCP) antibodies was performed using a commercially available ELISA kit. Measurement of blood rheumatoid factor (RF) was assayed by slide agglutination test for qualitative and semi-quantitative analysis. Blood C-reactive protein (CRP) was determined using latex-enhanced nephelometry. Disease severity score of RA patients was determined using DAS-28. DNA was isolated from white blood cells (WBCs), and (-174G/C) IL-6 gene promoter polymorphism was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. The study found significantly higher levels of serum IL-6 and ACCP in both untreated and treated RA patients compared to healthy controls. RF in RA patients was positive in 83.32% and negative in 16.67% of overall RA patients, whereas it was negative in 99% of healthy controls. CRP in RA patients was positive in 78.4% and negative in 21.6% of overall RA patients, while it was positive in 20% of healthy controls. Correlation between DAS-28 and IL-6 levels in untreated and treated RA patients showed a significant positive correlation. Correlation between IL-6 and ACCP in untreated and treated RA patients was also significantly positive. Correlation between DAS-28 and ACCP in untreated and treated RA patients was a significant positive correlation. The genotype distribution of (-174G/C) IL-6 gene promoter polymorphism in patients was 80% GG, 18.3% GC, and 1.6% CC, whereas in healthy controls it was 98.3% GG, 1.6% GC, and 0% CC. The relation between IL-6 levels and DAS-28 with genotyping of (-174G/C) IL-6 gene promoter polymorphism in untreated and treated RA patients showed a significant positive association. High levels of IL-6 and its positive correlation with DAS-28 suggest a possible role of IL-6 in the pathogenesis of RA. Moreover, these biomarkers can be used as markers of disease activity in the diagnosis and treatment of RA. The (-174G/C) IL-6 polymorphisms are also associated with RA risk, and the C allele of IL-6 promoter polymorphism dramatically increases susceptibility to RA in the Babylon population. This finding suggests that (-174G/C) IL-6 gene promoter polymorphism may also be used as another genetic marker for the onset and development of RA in the Babylon population.

كلمات الباحثين

Rheumatoid arthritis, IL-6, (-174G/C) IL-6 promoter polymorphism, ACCP, RF, CRP, DAS-28, genetic marker

إشراف وإعداد

الإشراف

صباح جاسم الربيعي, عبد السميع حسن الطائي

الإعداد

سارة حسين عيدان

الاقتباسات الببليوغرافية